As we reflect on the impactful milestones of 2024, we at AbClo are proud to celebrate a year marked by remarkable achievements, groundbreaking research, and continued growth in the adoption of our abdominal fascia closure system.
From innovative health economics studies to expanded clinical training initiatives, AbClo has solidified its position as a transformative solution in open abdomen management and continues to do so as we enter 2025.
Here are some of the key highlights from our year:
1. Advancing Evidence With Health Economics Research
This year, the publication Economic Analysis of AbClo: A Novel Abdominal Fascia Closure Device for Patients With an Open Abdomen Following Trauma or Acute Abdominal Surgery marked a significant addition to the benefits of using AbClo. Authored by Derek Chew & Taranvir Dayal, the study provides a comprehensive analysis of the cost-effectiveness and clinical benefits of the AbClo device.
The findings underscore the long-term value of early adoption, demonstrating improved patient outcomes and reduced healthcare resource utilization.
Read the full publication here.
2. Early Application Being A Clear Advantage
As clinical evidence and physicians alike continue to show elevated outcomes with early and aggressive closure timelines, AbClo has presented itself as an effective supporting technique to further accelerate these closure goals.
Key insights in Early placement of a non-invasive, pressure-regulated, fascial reapproximation device improves reduction of the fascial gap in open abdomens: a retrospective cohort study (published in The Journal of Trauma and Acute Care Open) reveals the critical role of early intervention in achieving optimal outcomes for patients while reducing overall costs.
Explore the Early vs. Late placement of AbClo insights here.
3. “Don’t Fear the Open Abdomen”
“Do Not Fear the Open Abdomen” is a recent commentary from Dr. Mejia Morales and Dr. Hampton from The University of Chicago that highlights the historical significance open abdomens provide as a surgical care option and the relevant issues we still face today, including; the lack of standardized care options that offer high success rates for fascial traction.
With the introduction of AbClo and concomitant NPWT devices such as AbThera; effective, replicable and guideline compliant (EAST, 2022) management of open abdomens is now possible. As these techniques become more standardized, so will the reduction of fear related to open abdomen procedures.
Read the thought-provoking article here.
4. Clinical Adoption on the Rise
Across clinical sites globally, the adoption of AbClo has grown exponentially. Every site that has evaluated AbClo has chosen to fully integrate it into their practice which is a testament to its reliability and impact on patient care.
5. Empowering Over 800 Professionals With Hands-On Training
Led by the exceptional expertise of Taranvir Dayal, AbClo has trained over 800 healthcare professionals in the device’s proper use and integration into clinical workflows.
Taranvir’s dedication to knowledge-sharing has been instrumental in AbClo’s widespread adoption and shown well through the customer resources made available to all AbClo users. In addition to on-site training, AbClo users gain access to virtual training modules, courses and videos providing extensive information on everything AbClo.
The creation of AbClo’s open abdominal superuser group will continue to expand interprofessional thought exchange for open abdomen care, further increasing the standardization and improvement in care for all.
Learn more about Taranvir’s training contributions here.
2025 & Beyond
With ongoing research, expanded clinical partnerships, and a continued focus on improving patient outcomes, AbClo is set to shift the paradigm of the future abdominal closure technology.
Thank you to our dedicated team, clinicians, and partners for making this year such a groundbreaking one. Here’s to continued success and innovation in the years ahead!
To learn more about AbClo, click here.